MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Alkermes PLC

Cerrado

SectorSalud

30.22 -1.63

Resumen

Variación precio

24h

Actual

Mínimo

30.06

Máximo

30.55

Métricas clave

By Trading Economics

Ingresos

65M

87M

Ventas

84M

391M

P/B

Media del Sector

15.541

36.442

Margen de beneficio

22.295

Empleados

1,800

EBITDA

99M

113M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+35.78% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

998M

5.3B

Apertura anterior

31.85

Cierre anterior

30.22

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

159 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Alkermes PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 oct 2025, 18:13 UTC

Principales Movimientos del Mercado

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 oct 2025, 17:05 UTC

Principales Movimientos del Mercado

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17 oct 2025, 15:03 UTC

Principales Movimientos del Mercado

Obook Shares Sink Following Public Debut

17 oct 2025, 14:41 UTC

Principales Movimientos del Mercado

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17 oct 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct 2025, 22:15 UTC

Charlas de Mercado

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct 2025, 21:15 UTC

Charlas de Mercado

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 20:34 UTC

Charlas de Mercado

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 oct 2025, 20:27 UTC

Charlas de Mercado

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 oct 2025, 19:46 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 oct 2025, 19:45 UTC

Charlas de Mercado

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 oct 2025, 18:45 UTC

Charlas de Mercado

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 oct 2025, 17:44 UTC

Charlas de Mercado

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 oct 2025, 17:35 UTC

Charlas de Mercado

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 16:14 UTC

Charlas de Mercado

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 oct 2025, 16:04 UTC

Charlas de Mercado

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 oct 2025, 15:58 UTC

Charlas de Mercado

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 oct 2025, 15:56 UTC

Ganancias

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 oct 2025, 15:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 15:43 UTC

Charlas de Mercado

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17 oct 2025, 14:58 UTC

Charlas de Mercado

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17 oct 2025, 14:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 oct 2025, 14:35 UTC

Charlas de Mercado
Ganancias

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Comparación entre iguales

Cambio de precio

Alkermes PLC Esperado

Precio Objetivo

By TipRanks

35.78% repunte

Estimación a 12 meses

Media 41.82 USD  35.78%

Máximo 54 USD

Mínimo 33 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

8

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

27.95 / 30.91Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

159 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat